Perimenopause at 40-45: what an AU GP looks for, what helps, what to ignore

What perimenopause actually is

Perimenopause is the hormonal transition leading up to menopause — the years during which ovarian function declines and reproductive hormone production becomes increasingly erratic. It typically begins in the early-to-mid 40s, lasts an average of 4–8 years, and ends one year after the final menstrual period (which retrospectively defines menopause).

The average AU age at menopause is 51–52 years. Some women experience earlier transition: early menopause (40–45) or premature ovarian insufficiency (before 40, ~1% of women) — both of which warrant specific workup, including assessment of cardiovascular and bone-health implications.

Common perimenopausal symptoms, in approximate prevalence order:

• Menstrual cycle changes — shorter cycles initially, then longer cycles, skipped periods, heavier bleeding episodes
• Vasomotor symptoms — hot flushes, night sweats (occur in ~75% of women, often the most disruptive)
• Sleep disturbance — primarily night-sweat-driven, but also primary perimenopausal insomnia
• Mood changes — irritability, anxiety, low mood; increased risk of clinical depression
• Cognitive symptoms — “brain fog”, word-finding difficulty, reduced verbal fluency
• Vaginal and urinary symptoms — vaginal dryness, dyspareunia, urinary frequency, recurrent UTIs
• Joint aches — diffuse musculoskeletal aches, often new in perimenopause
• Skin and hair changes
• Libido reduction
• Weight redistribution — central adiposity increase even without overall weight gain

This page covers what AU general practice actually offers, what the evidence supports, and what’s marketed beyond it.

A. Core clinical — the AU general practice workup

For a woman in her 40s presenting with typical perimenopausal symptoms, the RACGP and Australasian Menopause Society approach is largely clinical diagnosis based on the symptom pattern + cycle changes — rather than chasing hormone levels.

A standard long consultation (MBS item 36 or 44) covers:

• Symptom history — onset, severity, impact on function, sleep, work, relationships
• Cycle history — last menstrual period, cycle pattern, bleeding pattern (heavy bleeding warrants its own workup per eTG)
• Mood screen — PHQ-9 and GAD-7 where indicated
• Cardiovascular risk — calculated CVD risk becomes increasingly relevant in this age band; menopause shifts the cardiovascular trajectory
• Bone health — DXA scan eligibility considered (osteoporosis risk increases post-menopause)
• Cancer screening status — cervical screening (5-yearly HPV test, AU NCSP), breast screening (BreastScreen 50+ or earlier if family history), bowel screening (NBCSP 50+)
• Contraception status — pregnancy is still possible in perimenopause until 12 months post final period (or longer if under 50)
• Pre-existing conditions — hypertension, diabetes, mood disorders, migraine — all may change in perimenopause

Hormone testing is selective. FSH and oestradiol fluctuate dramatically during perimenopause; a single result rarely changes management. Worth testing when:

• Symptoms in woman under 45 (rule out POI)
• Atypical features
• Contraception decisions depend on ovulation status
• Suspected secondary cause (thyroid, prolactin, adrenal)

B. Menopausal hormone therapy (MHT) — what the AU evidence supports

The Australasian Menopause Society and Jean Hailes for Women’s Health coordinate the AU MHT framework. Key points:

Most effective treatment for moderate-to-severe vasomotor symptoms. Effect size markedly larger than non-hormonal options.

Favourable benefit/risk profile in healthy women under 60 within 10 years of menopause. The 2002 Women’s Health Initiative trial produced widespread overcaution that has been substantially revised — the WHI population was older (average 63) and most participants were many years post-menopause when started. The Manson 2017 JAMA reanalysis found no significant difference in all-cause mortality with MHT vs placebo over 18 years of follow-up.

Formulations. TGA-approved options include estradiol (oral or transdermal patch/gel), conjugated oestrogens, micronized progesterone (Prometrium), medroxyprogesterone, dydrogesterone (in combination preparations), and tibolone. Transdermal estradiol carries lower VTE risk than oral.

Risks. Small absolute increase in breast cancer with combined therapy used long-term; VTE (especially oral oestrogen); stroke risk slightly elevated in older women on oral oestrogen. Individual risk assessment per the Stuenkel guideline.

Contraindications. Current breast cancer, oestrogen-sensitive cancer, undiagnosed vaginal bleeding, severe liver disease, active VTE — among others. The RACGP and AMS resources cover these comprehensively.

C. Non-hormonal options when MHT isn’t appropriate

For women with contraindications, intolerance, or preference against MHT:

Option	Indication
SSRIs / SNRIs (paroxetine, escitalopram, venlafaxine)	Reduce hot flushes ~50%; co-treats mood symptoms
Gabapentin	Night-time vasomotor symptoms, sleep disturbance
Clonidine	Vasomotor symptoms (less commonly used now)
Vaginal oestrogen (local, low-dose)	Vaginal/urinary symptoms only; not contraindicated even with breast cancer history in many cases (specialist liaison)
CBT for vasomotor symptoms	Moderate evidence; reduces symptom-related distress
Regular aerobic + resistance exercise	Mood, sleep, bone density, cardiovascular
Weight management	Reduces hot flush frequency in overweight women
Alcohol and caffeine moderation	Reduces hot flush frequency in many women

NPS MedicineWise covers prescribing details. eTG Psychotropic and Endocrinology chapters provide AU-specific dosing.

D. What the marketing pushes beyond the evidence

Compounded “bioidentical” hormones. The term is marketing — many TGA-approved MHT formulations are themselves bioidentical (estradiol, micronized progesterone, estriol cream). The marketing distinction is usually between TGA-approved bioidenticals and compounded preparations from compounding pharmacies. The latter are not TGA-evaluated for the specific product’s safety/quality/efficacy, lack consistent dosing, and may include untested combinations. RACGP, RANZCOG, Australasian Menopause Society all advise using TGA-approved formulations where available.

“Adrenal fatigue” diagnoses. Not recognised in mainstream endocrinology. Common during midlife when stress, perimenopause, sleep disturbance, and lifestyle factors converge — but the marketed “adrenal fatigue” framing is not supported. Real adrenal insufficiency is a different condition (Addison’s, secondary adrenal insufficiency) managed by endocrinology.

Expensive supplement protocols. Maca, black cohosh, evening primrose oil, red clover — variably-studied for vasomotor symptoms with generally modest effect sizes. Reasonable to trial; not equivalent to MHT in effect.

“Detox” or “cleanse” protocols. Not supported by AU primary tier for any perimenopausal indication.

Branded “midlife reset” programmes. Most package legitimate components (CBT, exercise, dietary pattern, sleep hygiene) with weak or unsupported claims (specific supplement stacks, adrenal-focused testing, restrictive elimination diets). The legitimate components are accessible via Medicare-funded pathways at far lower cost.

Australian access pathway

Practical AU pathway for a woman seeking help with perimenopausal symptoms:

1. GP long consultation (MBS items 36/44) — clinical workup as above
2. Mental Health Treatment Plan (items 2715/2717) if mood symptoms are prominent — 10 subsidised psychology sessions
3. GP Management Plan (item 721) if co-morbidities (hypertension, diabetes, depression) warrant chronic-disease coordination
4. Heart Health Check (item 699) — annual cardiovascular risk assessment becomes increasingly relevant
5. Specialist referral — gynaecologist or endocrinologist for complex cases, treatment-resistant symptoms, contraindications to MHT, or premature ovarian insufficiency
6. Jean Hailes for Women’s Health — AU consumer resource and clinician directory specialising in women’s health
7. Bone density assessment — DXA scan eligibility per RACGP Red Book and Royal Australian College of Radiologists guidance

(MBS / PBS items verified 2026-05-17 via WebSearch — workspace egress to mbsonline.gov.au + pbs.gov.au still blocked; spot-check confirms current.)

When to call sooner rather than later

For perimenopausal symptoms specifically — not urgent, but worth a proper consultation when:

• Sleep is significantly disrupted for more than a few weeks
• Vasomotor symptoms are impairing work, relationships, or quality of life
• Mood symptoms are significant (not just transient irritability)
• Heavy menstrual bleeding (requires its own workup — anaemia, fibroids, endometrial assessment)
• Bleeding more than 12 months after the last period (always warrants workup — endometrial cancer rule-out)
• Symptoms in a woman under 45 (rule out POI)

Mental-health crisis support: Lifeline 13 11 14, Beyond Blue 1300 22 4636.

What this article is and is not

This is general health information drawn from current Australian general practice guidelines, the Australasian Menopause Society, Jean Hailes for Women’s Health, RANZCOG, and major peer-reviewed menopause trials. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about specific treatment — including MHT — are made with your own GP and treating clinicians, who can assess your individual risk profile.

For Australian consumer-friendly sources: Jean Hailes, HealthDirect — Menopause, Better Health Channel, Australasian Menopause Society.

---

Sources cited

1. RACGP
2. Australasian Menopause Society
3. Jean Hailes for Women’s Health
4. RANZCOG
5. Therapeutic Guidelines (eTG)
6. Australian Medicines Handbook
7. NPS MedicineWise
8. HealthDirect — Menopause
9. Better Health Channel
10. Beyond Blue
11. Heart Foundation — CVD guideline
12. Manson JE et al. — MHT and long-term mortality (JAMA 2017)
13. Stuenkel CA et al. — Menopause treatment guideline (J Clin Endocrinol Metab 2015)